Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

被引:35
|
作者
De Wolfe, T. J. [1 ,2 ]
Eggers, S. [3 ]
Barker, A. K. [3 ]
Kates, A. E. [2 ,4 ]
Dill-McFarland, K. A. [5 ]
Suen, G. [5 ]
Safdar, N. [2 ,4 ]
机构
[1] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15260 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Infect Dis, Madison, WI 53706 USA
[3] Univ Wisconsin, Madison Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA
[4] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA
[5] Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA
来源
PLOS ONE | 2018年 / 13卷 / 09期
基金
美国国家卫生研究院; 美国食品与农业研究所;
关键词
FECAL MICROBIOTA; SEQUENCE DATA; RESISTANCE; KEGG;
D O I
10.1371/journal.pone.0204253
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Perturbations in the gastrointestinal microbiome caused by antibiotics are a major risk factor for Clostridium difficile infection (CDI). Probiotics are often recommended to mitigate CDI symptoms; however, there exists only limited evidence showing probiotic efficacy for CDI. Here, we examined changes to the GI microbiota in a study population where probiotic treatment was associated with significantly reduced duration of CDI diarrhea. Subjects being treated with standard of care antibiotics for a primary episode of CDI were randomized to probiotic treatment or placebo for 4 weeks. Probiotic treatment consisted of a daily multi-strain capsule (Lactobacillus acidophilus NCFM, ATCC 700396; Lactobacillus paracasei Lpc-37, ATCC SD5275; Bifidobacterium lactis Bi-07, ATCC SC5220; Bifidobacterium lactis B1-04, ATCC SD5219) containing 1.7 x 10(10) CFUs. Stool was collected and analyzed using 16S rRNA sequencing. Microbiome analysis revealed apparent taxonomic differences between treatments and timepoints. Subjects administered probiotics had reduced Verrucomicrobiaceae at week 8 compared to controls. Bacteroides were significantly reduced between weeks 0 to 4 in probiotic treated subjects. Ruminococcus (family Lachnospiraceae), tended to be more abundant at week 8 than week 4 within the placebo group and at week 8 than week 0 within the probiotic group. Similar to these results, previous studies have associated these taxa with probiotic use and with mitigation of CDI symptoms. Compositional prediction of microbial community function revealed that subjects in the placebo group had microbiomes enriched with the iron complex transport system, while probiotic treated subjects had microbiomes enriched with the antibiotic transport system. Results indicate that probiotic use may impact the microbiome function in the face of a CDI; yet, more sensitive methods with higher resolution are warranted to better elucidate the roles associated with these changes. Continuing studies are needed understand probiotic effects on microbiome structure and function and the resulting impacts on CDI.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection
    Khanna, Sahil
    Pardi, Darrell S.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (10) : 1145 - 1152
  • [2] Clostridium difficile Infection: Fecal Microbiota Transfer versus Antibiotic Treatment
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (06):
  • [3] Antibiotic Treatment for Clostridium difficile Infection in Adults
    Wilson, Amanda
    AMERICAN JOURNAL OF NURSING, 2018, 118 (07) : 63 - 63
  • [4] Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection
    Zackular, Joseph P.
    Moore, Jessica L.
    Jordan, Ashley T.
    Juttukonda, Lillian J.
    Noto, Michael J.
    Nicholson, Maribeth R.
    Crews, Jonathan D.
    Semler, Matthew W.
    Zhang, Yaofang
    Ware, Lorraine B.
    Washington, M. Kay
    Chazin, Walter J.
    Caprioli, Richard M.
    Skaar, Eric P.
    NATURE MEDICINE, 2016, 22 (11) : 1330 - 1334
  • [5] Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection
    Joseph P Zackular
    Jessica L Moore
    Ashley T Jordan
    Lillian J Juttukonda
    Michael J Noto
    Maribeth R Nicholson
    Jonathan D Crews
    Matthew W Semler
    Yaofang Zhang
    Lorraine B Ware
    M Kay Washington
    Walter J Chazin
    Richard M Caprioli
    Eric P Skaar
    Nature Medicine, 2016, 22 : 1330 - 1334
  • [6] The microbiota and immune response during Clostridium difficile infection
    Buonomo, Erica L.
    Petri, William A., Jr.
    ANAEROBE, 2016, 41 : 79 - 84
  • [7] Combination Immunomodulator and Antibiotic Treatment in Patients With Inflammatory Bowel Disease and Clostridium difficile Infection
    Ben-Horin, Shomron
    Margalit, Maya
    Bossuyt, Peter
    Maul, Jochen
    Shapira, Yami
    Bojic, Daniela
    Chermesh, Irit
    Al-Rifai, Ahmad
    Schoepfer, Alain
    Bosani, Matteo
    Allez, Matthieu
    Lakatos, Peter Laszlo
    Bossa, Fabrizio
    Eser, Alexander
    Stefanelli, Tommaso
    Carbonnel, Franck
    Katsanos, Konstantinos
    Checchin, Davide
    Saenz De Miera, Ines
    Chowers, Yehuda
    Moran, Gordon William
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (09) : 981 - 987
  • [8] Fecal Microbiota Transplantation for Treatment of Clostridium difficile Infection
    Dai, Cong
    Jiang, Min
    Sun, Ming-jin
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2015, 49 (02) : 171 - 172
  • [9] Fecal microbiota transplantation for the treatment of Clostridium difficile infection
    Rao, Krishna
    Safdar, Nasia
    JOURNAL OF HOSPITAL MEDICINE, 2016, 11 (01) : 56 - 61
  • [10] Effect of the administration of a probiotic with a combination of Lactobacillus and Bifidobacterium strains on antibiotic-associated diarrhea
    Garcia Trallero, Olivia
    Herrera Serrano, Luis
    Bibian Ingles, Montse
    Roche Valles, David
    Maria Rodriguez, Ana
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (03) : 268 - 272